Patents by Inventor Anna Shenderova

Anna Shenderova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Apolipoprotein A-I mimics
    Patent number: 9981008
    Abstract: Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: May 29, 2018
    Assignee: Cerenis Therapeutics Holding SA
    Inventors: Jean-Louis Dasseux, Anna Shenderova Schwendeman, Lingyu Zhu
  • APOLIPOPROTEIN A-I MIMICS
    Publication number: 20160324923
    Abstract: Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.
    Type: Application
    Filed: July 11, 2016
    Publication date: November 10, 2016
    Inventors: Jean-Louis Dasseux, Anna Shenderova Schwendeman, Lingyu Zhu
  • Apolipoprotein A-I mimics
    Patent number: 9388232
    Abstract: Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: July 12, 2016
    Assignee: Cerenis Therapeutics Holding SA
    Inventors: Jean-Louis Dasseux, Anna Shenderova Schwendeman, Lingyu Zhu
  • APOLIPOPROTEIN A-I MIMICS
    Publication number: 20150141330
    Abstract: Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.
    Type: Application
    Filed: February 5, 2015
    Publication date: May 21, 2015
    Inventors: Jean-Louis Dasseux, Anna Shenderova Schwendeman, Lingyu Zhu
  • Apolipoprotein A-I mimics
    Patent number: 8993597
    Abstract: Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: March 31, 2015
    Assignee: Cerenis Therapeutics Holding SA
    Inventors: Jean-Louis Dasseux, Anna Shenderova Schwendeman, Lingyu Zhu
  • APOLIPOPROTEIN A-I MIMICS
    Publication number: 20130231459
    Abstract: Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.
    Type: Application
    Filed: February 13, 2013
    Publication date: September 5, 2013
    Applicant: CERENIS THERAPEUTICS HOLDING SA
    Inventors: Jean-Louis Dasseux, Anna Shenderova Schwendeman, Lingyu Zhu
  • Apolipoprotein A-I mimics
    Patent number: 8378068
    Abstract: Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: February 19, 2013
    Assignee: Cerenis Therapeutics Holding SA
    Inventors: Jean-Louis Dasseux, Anna Shenderova Schwendeman, Lingyu Zhu
  • APOLIPOPROTEIN A-I MIMICS
    Publication number: 20100267631
    Abstract: Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.
    Type: Application
    Filed: February 12, 2010
    Publication date: October 21, 2010
    Inventors: JEAN-LOUIS DASSEUX, ANNA SHENDEROVA SCHWENDEMAN, LINGYU ZHU
  • METHOD OF TREATING DYSLIPIDEMIC DISORDER
    Publication number: 20080269111
    Abstract: The invention provides methods of treating or preventing a condition or disorder associated with dyslipidemia with compositions comprising apolipoprotein-sphingomyelin complexes. The methods of the invention permit reduction, by 4- to 20-fold, of the amount of apolipoprotein required for therapeutic administration to bring about an ameliorative effect.
    Type: Application
    Filed: August 22, 2007
    Publication date: October 30, 2008
    Inventors: JEAN-LOUIS H. DASSEUX, Anna A. Shenderova, Thomas J. Rea
  • METHODS FOR STABILIZING BIOLOGICALLY ACTIVE AGENTS ENCAPSULATED IN BIODEGRADABLE CONTROLLED-RELEASE POLYMERS
    Publication number: 20080182909
    Abstract: Methods for reducing or inhibiting the irreversible inactivation of water-soluble biologically active agents in biodegradable polymeric delivery systems which are designed to release such agents over a prolonged period of time, such as PLGA delivery systems are provided. The method comprises preparing PLGA delivery systems whose microclimate, i.e. the pores where the active agent resides, uniformly or homogenously maintain a pH of between 3 and 9, preferably between 4 and 8, more preferably between 5 and 7.5 during biodegradation.
    Type: Application
    Filed: September 27, 2007
    Publication date: July 31, 2008
    Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Steven P. Schwendeman, Gaozhong Zhu, Hanne Bentz, Jeffrey A. Hubbell, Wenlei Jiang, Anna Shenderova, Jichao Kang
  • Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
    Publication number: 20040105878
    Abstract: Methods for reducing or inhibiting the irreversible inactivation of water-soluble biologically active agents in biodegradable polymeric delivery systems which are designed to release such agents over a prolonged period of time, such as PLGA delivery systems are provided. The method comprises preparing a PLGA delivery systems whose microclimate, i.e. the pores where the active agent resides, uniformly or homogenously maintain a pH of between 3 and 9, preferably between 4 and 8, more preferably between 5 and 7.5 during biodegradation.
    Type: Application
    Filed: November 3, 2003
    Publication date: June 3, 2004
    Inventors: Steven P. Schwendeman, Gaozhong Zhu, Hanne Bentz, Jeffrey A. Hubbell, Wenlei Jiang, Anna Shenderova, Jichao Kang
  • Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
    Patent number: 6743446
    Abstract: Methods for reducing or inhibiting the irreversible inactivation of water-soluble biologically active agents in biodegradable polymeric delivery systems which are designed to release such agents over a prolonged period of time, such as PLGA delivery systems are provided. The method comprises preparing a PLGA delivery systems whose microclimate, i.e. the pores where the active agent resides, uniformly or homogenously maintain a pH of between 3 and 9, preferably between 4 and 8, more preferably between 5 and 7.5 during biodegradation.
    Type: Grant
    Filed: December 15, 2000
    Date of Patent: June 1, 2004
    Assignee: The Ohio State University Research Foundation
    Inventors: Steven P. Schwendeman, Gaozhong Zhu, Hanne Bentz, Jeffrey A. Hubbell, Wenlei Jiang, Anna Shenderova, Jichao Kang
  • Method of treating dyslipidemic disorders
    Publication number: 20040067873
    Abstract: The invention provides methods of treating or preventing a condition or disorder associated with dyslipidemia with compositions comprising apolipoprotein-sphingomyelin complexes. The methods of the invention permit reduction, by 4- to 20-fold, of the amount of apolipoprotein required for therapeutic administration to bring about an ameliorative effect.
    Type: Application
    Filed: May 16, 2003
    Publication date: April 8, 2004
    Inventors: Jean-Louis H. Dasseux, Anna A. Shenderova, Thomas J. Rea
  • Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
    Publication number: 20020009493
    Abstract: Methods for reducing or inhibiting the irreversible inactivation of water-soluble biologically active agents in biodegradable polymeric delivery systems which are designed to release such agents over a prolonged period of time, such as PLGA delivery systems are provided. The method comprises preparing a PLGA delivery systems whose microclimate, i.e. the pores where the active agent resides, uniformly or homogenously maintain a pH of between 3 and 9, preferably between 4 and 8, more preferably between 5 and 7.5 during biodegradation.
    Type: Application
    Filed: December 15, 2000
    Publication date: January 24, 2002
    Inventors: Steven P. Schwendeman, Gaozhong Zhu, Hanne Bentz, Jeffrey A. Hubbell, Wenlei Jiang, Anna Shenderova, Jichao Kang